Mural Oncology Q1 EPS Forecast Decreased by HC Wainwright

Mural Oncology plc (NASDAQ:MURA) – Analysts at HC Wainwright lowered their Q1 2025 earnings estimates for Mural Oncology in a report released on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($2.13) per share for the quarter, down from their prior forecast of ($2.05). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Mural Oncology’s current full-year earnings is ($7.54) per share. HC Wainwright also issued estimates for Mural Oncology’s Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($5.65) EPS, FY2026 earnings at ($3.81) EPS, FY2027 earnings at ($3.41) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at ($1.45) EPS.

Mural Oncology (NASDAQ:MURA) last issued its earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same quarter in the prior year, the business earned ($3.57) EPS.

Mural Oncology Trading Up 4.4 %

Shares of NASDAQ:MURA opened at $4.07 on Monday. The business has a fifty day simple moving average of $3.88 and a 200 day simple moving average of $3.60. Mural Oncology has a 1 year low of $2.87 and a 1 year high of $5.12. The firm has a market cap of $70.12 million, a price-to-earnings ratio of -0.45 and a beta of 3.66.

Institutional Investors Weigh In On Mural Oncology

Several institutional investors have recently made changes to their positions in MURA. Commerce Bank acquired a new position in Mural Oncology in the third quarter worth approximately $39,000. FMR LLC increased its stake in shares of Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after purchasing an additional 11,423 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Mural Oncology during the 3rd quarter valued at $340,000. Geode Capital Management LLC lifted its stake in shares of Mural Oncology by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after purchasing an additional 4,731 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Mural Oncology in the 4th quarter valued at $181,000. 80.21% of the stock is currently owned by institutional investors and hedge funds.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.